Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
7.42
+0.05 (0.68%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Myriad Genetics Stock Forecast
Stock Price Forecast
The 15 analysts with 12-month price forecasts for Myriad Genetics stock have an average target of 20.17, with a low estimate of 11 and a high estimate of 35. The average target predicts an increase of 171.83% from the current stock price of 7.42.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Myriad Genetics stock from 16 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 1 | 2 | 2 | 2 |
| Buy | 4 | 2 | 2 | 3 | 4 | 4 |
| Hold | 4 | 6 | 6 | 6 | 6 | 7 |
| Sell | 2 | 3 | 3 | 3 | 3 | 3 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 13 | 12 | 14 | 15 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $18 → $14 | Strong Buy | Maintains | $18 → $14 | +88.68% | Apr 17, 2025 |
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Apr 9, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $24 → $20 | Buy | Maintains | $24 → $20 | +169.54% | Apr 1, 2025 |
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $12 → $13 | Hold → Buy | Upgrades | $12 → $13 | +68.46% | Mar 12, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $14 → $12 | Hold | Maintains | $14 → $12 | +54.99% | Mar 4, 2025 |
Financial Forecast
Revenue This Year
862.43M
from 837.60M
Increased by 2.96%
Revenue Next Year
934.57M
from 862.43M
Increased by 8.36%
EPS This Year
0.08
from -1.41
EPS Next Year
0.28
from 0.08
Increased by 250.15%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 899.0M | 984.8M | 1.1B | ||
| Avg | 862.4M | 934.6M | 1.0B | ||
| Low | 803.8M | 833.3M | 865.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7.3% | 14.2% | 16.5% | ||
| Avg | 3.0% | 8.4% | 7.5% | ||
| Low | -4.0% | -3.4% | -7.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.11 | 0.43 | 0.74 | ||
| Avg | 0.08 | 0.28 | 0.47 | ||
| Low | 0.01 | 0.09 | 0.26 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 445.8% | 166.1% | ||
| Avg | - | 250.1% | 70.9% | ||
| Low | - | 11.8% | -4.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.